Clinical Trial Detail

NCT ID NCT04189445
Title Futibatinib in Patients With Specific FGFR Aberrations
Recruitment Not yet recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Taiho Oncology, Inc.
Indications

Advanced Solid Tumor

lymphoma

gastroesophageal junction adenocarcinoma

myeloid neoplasm

stomach cancer

Therapies

Futibatinib

Age Groups: senior adult

Additional content available in CKB BOOST